|
MARLBOROUGH, Mass. (AP) -- Drug developer Sepracor Inc. said Wednesday it is partnering with Portugal-based drug developer Bial to develop and sell a new epilepsy drug. Sepracor will file a new drug application with the Food and Drug Administration, as early as late 2008 or early 2009. Bial is entitled to a $75 million payment upfront, and milestone payments up to $100 million. The compound, called BIA 2-093, has already been tested in three late-stage studies involving more than 1,000 patients. Sepracor's drugs include Lunesta for insomnia and Xopenex for asthma. Shares of Sepracor closed at $26.25 Monday.
|